Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

AnaptysBio, Inc.

35 indications, side-by-side phase, drug & LoA

$56.07

+1.83 (+3.37%)

C 52Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.49 B
EPS
-0.86
P/E Ratio
-59.9 $
Value Trade
47.68 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    25.56 M

  • R&D Expenses

    33.99 M

  • Operating CF

    -25.92 M

  • Total Assets

    329.68 M

  • Total Liabilities

    329.68 M

  • Equity

    12.75 M

  • D/E Ratio

    12,345

-3.99 %
Week
15.81 %
1 Month
62.96 %
3 Month
168.4 %
6 Month
255.05 %
5 Year
459.86 %
All Time
Cash Data
Healthy

  • Cash Position

    286.45 M

  • Monthly Burn

    8.64 M

  • Runway

    32.2 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 12, 2026
Overview
Volume
422.71 K
52 Week Range
11.40 - 72.36
% held by Insiders
6.43 %
% held by Institutions
100.45 %
Enterprise Value
1.48 B
Total Shares
27.68 M
Short %
17.71 %
Float Shares
17.05 M
Company Description
HQ: 10770 WATERIDGE CIRCLE, SUITE ...
Founded:2005
Employees:104
https://www.anaptysbio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA Date example
imsidolimab generalized pustular psoriasis (GPP)
PDUFA
—
Biologics
Rare Diseases
imsidolimab generalized pustular psoriasis (GPP)
PDUFA
—
Biologics
Rare Diseases
imsidolimab generalized pustular psoriasis (GPP)
PDUFA
—
Biologics
Rare Diseases
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C52
Pipeline Score
$1.5B
Pipeline Value
Fair Value
Valuation Signal
2
Drugs Scored
1.0x
rNPV / MCap
Top 77%
Micro Cap
(rank 209 of 905)
Percentile Rank
AnaptysBio, Inc. carries a moderate pipeline score (52/100), with $3.6B risk-adjusted pipeline value, led by Etokimab in Atopic Dermatitis (Phase 2), across $95B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Etokimab
Monoclonal antibody		Atopic DermatitisPhase 2NCT0353375146% $2.0B COMPLETED 302 - -Dec 3, 2019 -May 24, 2023
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
rosnilimab
rheumatoid arthritis
Phase 2b
2025-08-07
rosnilimab
rheumatoid arthritis
Phase 2b
2025-08-07
rosnilimab
rheumatoid arthritis
Phase 2b
2025-08-07
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ANAB
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ANAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANAB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ANAB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ANAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest AnaptysBio, Inc. (ANAB) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ANAB ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Rheumatoid Arthritis #9 of 28 PHASE 2 Rosnilimab
ABBV LLY BMY
$4.2B 0.9 FOLLOWER
Ulcerative Colitis #11 of 17 PHASE 2 Rosnilimab
SNY JNJ LLY
$6.5B 0.88 FOLLOWER